Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05 2023 - 7:00AM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that Chandler D.
Robinson, MD, Monopar’s Chief Executive Officer, will present at
the H.C. Wainwright 25th Annual Global Investment Conference. The
Company’s presentation will be webcast beginning on Monday,
September 11, 2023 at 7:00 a.m. ET. In person one-on-one
meetings will take place at the Lotte New York Palace, NY, NY from
September 11 - 13, 2023.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical
company focused on developing innovative treatments for cancer
patients. Monopar's pipeline consists of camsirubicin (Phase 1b)
for the treatment of advanced soft tissue sarcoma; MNPR-101, a
late-stage preclinical antibody for radiopharmaceutical use in
advanced cancers; and MNPR-202, an early-stage camsirubicin analog
for various cancers. For more information,
visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc. Investor Relations
Kim R. Tsuchimoto Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates: Twitter:
@MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Apr 2024 to May 2024
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From May 2023 to May 2024